Home » Stocks » DNAY

Codex DNA, Inc. (DNAY)

Stock Price: $18.50 USD 2.50 (15.63%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
After-hours: $18.65 +0.15 (0.81%) Jun 18, 7:45 PM
Market Cap 522.24M
Revenue (ttm) 7.52M
Net Income (ttm) -21.57M
Shares Out 28.23M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $18.50
IPO Price $16.00
Change ($) 2.50
Change (%) 15.63%
Day's Open 20.00
Day's Range 17.13 - 21.75
Day's Volume 3,906,822
52-Week Range 17.13 - 21.75

News

Hide News

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today ...

2 days ago - GlobeNewsWire

Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that...

6 days ago - GlobeNewswire

Codex DNA, Inc. has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

About DNAY

Codex DNA is a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. We believe our BioXp system can democratize synthetic biology by simplifying the process of building DNA and mR... [Read more...]

Industry
Medical Devices
IPO Date
Jun 18, 2021
CEO
Todd R. Nelson
Employees
101
Stock Exchange
NASDAQ
Ticker Symbol
DNAY
Full Company Profile

Financial Performance

In 2020, Codex DNA's revenue was $6.58 million, an increase of 36.86% compared to the previous year's $4.81 million. Losses were -$18.01 million, 116.9% more than in 2019.

Financial Statements